Hope Elizabeth Uronis, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 435 Seeley G. Mudd Building, Box 2823, Durham, NC 27710
Phone (919) 681-3480
In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 2005 - 2007
  • Chief Medical Resident -Duke Hospital, Medicine, Duke University, 2004 - 2005
  • Fellow in Hematology-Oncology, Medicine, Duke University, 2003 - 2004
  • Medical Resident, Medicine, Duke University, 2000 - 2003
  • M.D., State University of New York at Buffalo, 2000

Publications

Mettu, NB, Niedzwiecki, D, Rushing, C, Nixon, AB, Jia, J, Haley, S, Honeycutt, W, Hurwitz, H, Bendell, JC, and Uronis, H. "A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors." March 20, 2019.

PMID
30895346
Full Text

Catenacci, DVT, Park, H, Uronis, HE, Kang, Y-K, Ng, M, Gold, P, Lacy, J, Enzinger, PC, Park, S, Lee, K-W, Yen, J, Odegaard, J, Franovic, A, Baughman, J, Muth, J, Wynter-Horton, A, Wu, T, Wigginton, J, Davidson-Moncada, JK, and Bang, Y-J. "Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER21 gastric adenocarcinoma (GEA)." 43rd ESMO Congress (ESMO). Munich, GERMANY. October 19, 2018 - October 23, 2018.: OXFORD UNIV PRESS, October 1, 2018.

Scholars@Duke

Wang, J, Liu, SV, Uronis, HE, Wu, C, Mahalingam, D, Spira, A, Carter, L, Hu, X, Weems, G, Wilkins, HJ, Duska, LR, and Kelly, K. "Novel small-molecule RORc agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial." 43rd ESMO Congress (ESMO). Munich, GERMANY. October 19, 2018 - October 23, 2018.: OXFORD UNIV PRESS, October 1, 2018.

Scholars@Duke

Sohal, DPS, Kennedy, EB, Khorana, A, Copur, MS, Crane, CH, Garrido-Laguna, I, Krishnamurthi, S, Moravek, C, O'Reilly, EM, Philip, PA, Ramanathan, RK, Ruggiero, JT, Shah, MA, Urba, S, Uronis, HE, Lau, MW, and Laheru, D. "Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36, no. 24 (August 2018): 2545-2556.

PMID
29791286
Full Text

Vlahovic, G, Meadows, KL, Hatch, AJ, Jia, J, Nixon, AB, Uronis, HE, Morse, MA, Selim, MA, Crawford, J, Riedel, RF, Zafar, SY, Howard, LA, O'Neill, M, Meadows, JJ, Haley, ST, Arrowood, CC, Rushing, C, Pang, H, and Hurwitz, HI. "A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer." The Oncologist 23, no. 7 (July 2018): 782-790.

PMID
29572245
Full Text

Palta, M, Czito, BG, Duffy, E, Malicki, M, Niedzwiecki, D, Abbruzzese, JL, Uronis, HE, Blobe, GC, Blazer, DG, and Willett, C. "A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.": American Society of Clinical Oncology (ASCO), May 20, 2018.

Full Text

Kelly, K, Johnson, ML, Mahalingam, D, Liu, SV, Uronis, HE, and Wu, C. "A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule ROR gamma agonist to treat select solid tumors.": AMER SOC CLINICAL ONCOLOGY, May 20, 2018.

Full Text

Catenacci, DVT, Park, H, Uronis, HE, Kang, Y-K, Lacy, J, Enzinger, PC, Park, SH, Lee, KW, Ng, MCH, Gold, PJ, Yen, J, Franovic, A, Kelly, RJ, Wynter-Horton, A, Li, D, Muth, J, Baughman, JE, Hong, S, Davidson-Moncada, JK, and Bang, Y-J. "Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).": American Society of Clinical Oncology (ASCO), May 20, 2018.

Full Text

Jia, J, Niedzwiecki, D, Uronis, HE, Morse, M, Zafar, Y, Hsu, SD, Bolch, E, Nagy, RJ, Lanman, RB, Talasaz, A, Haley, S, Nixon, AB, and Strickler, JH. "A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.": American Society of Clinical Oncology (ASCO), May 20, 2018.

Full Text

Catenacci, DVT, Park, H, Lockhart, AC, Gold, PJ, Enzinger, PC, Nordstrom, JL, Hong, S, Hochster, HS, Kelly, RJ, Uronis, HE, Bendell, JC, Oh, SC, Park, SH, Kim, YH, Kang, Y-K, Lee, K-W, Ng, MCH, Wigginton, JM, Davidson-Moncada, JK, and Bang, Y-J. "Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA)." Gastrointestinal Cancers Symposium. San Francisco, CA. January 18, 2018 - January 20, 2018.: AMER SOC CLINICAL ONCOLOGY, February 1, 2018.

Scholars@Duke

Pages